Bioline Rx Ltd ADR (BLRX) Implied Volatility Current

Tracking BLRX implied volatility helps you identify when options premiums on Bioline Rx Ltd ADR are historically cheap or expensive, and where the best trades are hiding. Bioline Rx Ltd ADR implied volatility reflects the market's expectation of future price movement: when BLRX IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Bioline Rx Ltd ADR's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For BLRX, tracking metrics like BLRX IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on BLRX signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.

It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where BLRX implied volatility sits today versus where it has been. Our scanner ranks Bioline Rx Ltd ADR implied volatility against its historical range, surfaces extremes in BLRX IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Bioline Rx Ltd ADR IV is rich or cheap — measure it, then act on it.